PolyNovo’s breast product partner, Establishment Labs, has been reporting healthy sales growth.
Sales growth is reported to be 40% year on year and the company is on track to surpass US$100m in revenues this year. Although marketing authorization is still not received in the US (clinical trials are ongoing and FDA approval is targeted for 2022), Establishment Labs’ products are already selling in over 80 countries. Entry into China is expected this year.
Jefferies’ analysts are now predicting that Establishment labs will triple the size of its addressable market by 2023, opening up markets close to US$1 bn. It sees the company’s sales potentially growing to US$400m by 2025.
https://www.medtechdive.com/news/es...plant-opportunity-to-triple-jefferies/568603/
https://www.medtechdive.com/news/es...breast-implant-sales-on-track-for-100/567119/
Recent Bans of Textured Implants & Polynovo to Stop BIA ALCL?, page-68
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.58 |
Change
0.040(1.57%) |
Mkt cap ! $1.781B | |||
| Open | High | Low | Value | Volume |
| $2.56 | $2.59 | $2.53 | $3.881M | 1.517M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 10150 | $2.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.58 | 38947 | 2 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| PNV (ASX) Chart |